S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
NASDAQ:IFRX

InflaRx Stock Forecast, Price & News

$4.11
-0.72 (-14.91%)
(As of 12/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.87
$4.83
50-Day Range
$2.35
$5.58
52-Week Range
$2.23
$6.88
Volume
1.48 million shs
Average Volume
1.05 million shs
Market Capitalization
$177.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.71
30 days | 90 days | 365 days | Advanced Chart
Receive IFRX News and Ratings via Email

Sign-up to receive the latest news and ratings for InflaRx and its competitors with MarketBeat's FREE daily newsletter.


InflaRx logo

About InflaRx

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products include IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.

Headlines

InflaRx (NASDAQ:IFRX) Short Interest Down 23.2% in November
December 3, 2021 |  americanbankingnews.com
InflaRx (NASDAQ:IFRX) Given Average Rating of "Buy" by Brokerages
November 22, 2021 |  americanbankingnews.com
InflaRx (NASDAQ:IFRX) Short Interest Update
November 17, 2021 |  americanbankingnews.com
Calculating The Fair Value Of InflaRx N.V. (NASDAQ:IFRX)
November 8, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IFRX
Fax
N/A
Employees
49
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$3.14 per share

Profitability

Net Income
$-38.82 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$177.68 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/12/2021
Today
12/04/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/24/2022

MarketRank

Overall MarketRank

1.53 out of 5 stars

Medical Sector

1059th out of 1,390 stocks

Pharmaceutical Preparations Industry

500th out of 668 stocks

Analyst Opinion: 3.4Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












InflaRx (NASDAQ:IFRX) Frequently Asked Questions

Is InflaRx a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InflaRx in the last year. There are currently 1 sell rating, 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" InflaRx stock.
View analyst ratings for InflaRx
or view top-rated stocks.

How has InflaRx's stock been impacted by Coronavirus?

InflaRx's stock was trading at $3.23 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IFRX shares have increased by 27.2% and is now trading at $4.11.
View which stocks have been most impacted by COVID-19
.

Are investors shorting InflaRx?

InflaRx saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 666,800 shares, a drop of 23.2% from the October 31st total of 868,200 shares. Based on an average daily trading volume, of 2,980,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 1.8% of the company's shares are short sold.
View InflaRx's Short Interest
.

When is InflaRx's next earnings date?

InflaRx is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for InflaRx
.

How were InflaRx's earnings last quarter?

InflaRx (NASDAQ:IFRX) issued its earnings results on Wednesday, May, 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.05.
View InflaRx's earnings history
.

What price target have analysts set for IFRX?

5 Wall Street analysts have issued 12-month price objectives for InflaRx's stock. Their forecasts range from $2.50 to $16.00. On average, they anticipate InflaRx's stock price to reach $9.90 in the next twelve months. This suggests a possible upside of 140.9% from the stock's current price.
View analysts' price targets for InflaRx
or view top-rated stocks among Wall Street analysts.

Who are InflaRx's key executives?

InflaRx's management team includes the following people:
  • Niels Christoph Riedemann, Chief Executive Officer & Executive Director
  • Thomas Taapken, Chief Financial Officer
  • Renfeng Guo, Executive Director & Chief Scientific Officer
  • Maria Habel, Head-Research & Development
  • Korinna Pilz, Chief Clinical Development Officer

What other stocks do shareholders of InflaRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InflaRx investors own include Dynavax Technologies (DVAX), Gilead Sciences (GILD), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), AbbVie (ABBV), OPKO Health (OPK), Capricor Therapeutics (CAPR), Citius Pharmaceuticals (CTXR), (KDMN) and Moderna (MRNA).

When did InflaRx IPO?

(IFRX) raised $100 million in an initial public offering (IPO) on Wednesday, November 8th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

What is InflaRx's stock symbol?

InflaRx trades on the NASDAQ under the ticker symbol "IFRX."

Who are InflaRx's major shareholders?

InflaRx's stock is owned by a number of institutional and retail investors. Top institutional investors include Morgan Stanley (1.67%), Great Point Partners LLC (1.28%), FNY Investment Advisers LLC (0.74%), Renaissance Technologies LLC (0.19%), Millennium Management LLC (0.11%) and Two Sigma Securities LLC (0.05%).

Which institutional investors are selling InflaRx stock?

IFRX stock was sold by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Renaissance Technologies LLC, Morgan Stanley, FNY Investment Advisers LLC, Raymond James & Associates, and Raymond James Financial Services Advisors Inc..

Which institutional investors are buying InflaRx stock?

IFRX stock was bought by a variety of institutional investors in the last quarter, including Two Sigma Securities LLC, Geode Capital Management LLC, Millennium Management LLC, and Two Sigma Investments LP.

How do I buy shares of InflaRx?

Shares of IFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is InflaRx's stock price today?

One share of IFRX stock can currently be purchased for approximately $4.11.

How much money does InflaRx make?

InflaRx has a market capitalization of $177.68 million. The company earns $-38.82 million in net income (profit) each year or ($1.32) on an earnings per share basis.

How many employees does InflaRx have?

InflaRx employs 49 workers across the globe.

What is InflaRx's official website?

The official website for InflaRx is www.inflarx.de.

Where are InflaRx's headquarters?

InflaRx is headquartered at WINZERLAER STR. 2, JENA 2M, 07745.

How can I contact InflaRx?

InflaRx's mailing address is WINZERLAER STR. 2, JENA 2M, 07745. The company can be reached via phone at 493641508180 or via email at [email protected].


This page was last updated on 12/4/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.